Cargando…

Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?

PURPOSE: Unlike therapy-related nausea and vomiting (chemotherapy or radiotherapy induced), nausea and vomiting (N/V) in patients with advanced cancer is often multicausal and thus presents unique challenges. Few professional guidelines address the palliative management of N/V, and those that do are...

Descripción completa

Detalles Bibliográficos
Autor principal: Wickham, Rita J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508252/
https://www.ncbi.nlm.nih.gov/pubmed/32974072
http://dx.doi.org/10.6004/jadpro.2020.11.5.4
_version_ 1783585392630431744
author Wickham, Rita J.
author_facet Wickham, Rita J.
author_sort Wickham, Rita J.
collection PubMed
description PURPOSE: Unlike therapy-related nausea and vomiting (chemotherapy or radiotherapy induced), nausea and vomiting (N/V) in patients with advanced cancer is often multicausal and thus presents unique challenges. Few professional guidelines address the palliative management of N/V, and those that do are insufficiently detailed to bolster clinical decision-making. Nonetheless, oncology advanced practitioners (APs) are frequently challenged to manage these high-impact symptoms. This requires collaborating with other oncology care providers and cultivating a knowledge base to educate and mentor professional colleagues to optimize N/V unrelated to treatment. METHODS: Literature reviewed included current and classic articles that address the physiologic bases of N/V related to disease and with malignant bowel obstruction, agents used to alleviate nausea or N/V, and nonpharmacologic adjunctive measures. This information was framed within palliative care and symptom management clinical experience. RESULTS: This review article summarizes what is known about the neuropharmacology of N/V in advanced disease. Focused assessment, pharmacologic agents (antiemetics, central neuromodulators, and peripheral prokinetic agents), and nondrug adjunctive measures that may be useful for N/V are included. CONCLUSIONS: Managing N/V in advanced cancer is a quality-of-life imperative that requires persistence and interprofessional collaboration among oncology APs and other clinicians to personalize management. This work can change the perception that N/V related to progressive disease is frequently intractable to one that considers it as a manageable clinical challenge.
format Online
Article
Text
id pubmed-7508252
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-75082522020-09-23 Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge? Wickham, Rita J. J Adv Pract Oncol Review PURPOSE: Unlike therapy-related nausea and vomiting (chemotherapy or radiotherapy induced), nausea and vomiting (N/V) in patients with advanced cancer is often multicausal and thus presents unique challenges. Few professional guidelines address the palliative management of N/V, and those that do are insufficiently detailed to bolster clinical decision-making. Nonetheless, oncology advanced practitioners (APs) are frequently challenged to manage these high-impact symptoms. This requires collaborating with other oncology care providers and cultivating a knowledge base to educate and mentor professional colleagues to optimize N/V unrelated to treatment. METHODS: Literature reviewed included current and classic articles that address the physiologic bases of N/V related to disease and with malignant bowel obstruction, agents used to alleviate nausea or N/V, and nonpharmacologic adjunctive measures. This information was framed within palliative care and symptom management clinical experience. RESULTS: This review article summarizes what is known about the neuropharmacology of N/V in advanced disease. Focused assessment, pharmacologic agents (antiemetics, central neuromodulators, and peripheral prokinetic agents), and nondrug adjunctive measures that may be useful for N/V are included. CONCLUSIONS: Managing N/V in advanced cancer is a quality-of-life imperative that requires persistence and interprofessional collaboration among oncology APs and other clinicians to personalize management. This work can change the perception that N/V related to progressive disease is frequently intractable to one that considers it as a manageable clinical challenge. Harborside Press LLC 2020-07 2020-07-01 /pmc/articles/PMC7508252/ /pubmed/32974072 http://dx.doi.org/10.6004/jadpro.2020.11.5.4 Text en © 2020 Harborside™ http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Wickham, Rita J.
Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?
title Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?
title_full Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?
title_fullStr Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?
title_full_unstemmed Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?
title_short Nausea and Vomiting Not Related to Cancer Therapy: Intractable Problem or Clinical Challenge?
title_sort nausea and vomiting not related to cancer therapy: intractable problem or clinical challenge?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508252/
https://www.ncbi.nlm.nih.gov/pubmed/32974072
http://dx.doi.org/10.6004/jadpro.2020.11.5.4
work_keys_str_mv AT wickhamritaj nauseaandvomitingnotrelatedtocancertherapyintractableproblemorclinicalchallenge